IL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice

Hepatology

Volumn 65, Issue 1, 2017, Pages 89-103

  Bergmann, Juri ^a,b   Müller, Miryam ^a   Baumann, Niklas ^a   Reichert, Manuel ^a,b   Heneweer, Carola ^b   Bolik, Julia ^a   Lücke, Karsten ^c   Gruber, Sabine ^d   Carambia, Antonella ^c   Boretius, Susanne ^b   Leuschner, Ivo ^b   Becker, Thomas ^b   Rabe, Björn ^a   Herkel, Johannes ^c   Wunderlich, F Thomas ^d   Mittrücker, Hans Willi ^c   Rose John, Stefan ^a   Schmidt Arras, Dirk ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOPOIETIN 1; ATM PROTEIN; ATR PROTEIN; BETA CATENIN; CASPASE 3; DIETHYLNITROSAMINE; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN GP 130; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEME OXYGENASE 1; HISTONE H2AX; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN P53; STAT3 PROTEIN; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER SIZE; CONTROLLED STUDY; DNA DAMAGE; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PHYSIOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; INTERLEUKIN-6; LIVER NEOPLASMS; MALE; MICE; SIGNAL TRANSDUCTION;

EID: 85006018001     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28874     Document Type: Article

References (41)

1. Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol 2016;64:1403–1415.
2. Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 2003;300:2101–2104.
3. Scheller Jü, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878–888.
4. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007;110:1748–1755.
5. Chalaris A, Gewiese J, Paliga K, Fleig L, Schneede A, Krieger K, et al. ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta 2010;1803:234–245.
6. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood 2008;111:1021–1028.
7. 4induced liver damage. Biochim Biophys Acta 2010;1802:1054–1061.
8. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel Gü et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456–469.
9. Villanueva A, Hernandez-Gea V, Llovet JM, Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013;10:34–42.
10. Deviere J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J, et al., High interleukin-6 serum levels and increased production by leucocytes in alcoholic liver cirrhosis. Correlation with IgA serum levels and lymphokines production. Clin Exp Immunol 1989;77:221–225.
11. Kakumu S, Shinagawa T, Ishikawa T, Yoshioka K, Wakita T, Ida N, Interleukin 6 production by peripheral blood mononuclear cells in patients with chronic hepatitis B virus infection and primary biliary cirrhosis. Gastroenterol Jpn 1993;28:18–24.
12. Soresi M, Giannitrapani L, D'Antona F, Florena AM, La Spada E, Terranova A, et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006;12:2563–2568.
13. Aleksandrova K, Boeing H, Nöthlings U, Jenab M, Fedirko V, Kaaks R, et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer. Hepatology 2014;60:858–871.
14. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005;121:977–990.
15. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121–124.
16. Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012;148:72–83.
17. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237–1245.
18. Calabrese V, Mallette FA, Deschênes-Simard X, Ramanathan S, Gagnon J, Moores A, et al. SOCS1 links cytokine signaling to p53 and senescence. Mol Cell 2009;36:754–767.
19. Meek DW. Regulation of the p53 response and its relationship to cancer. Biochem J 2015;469:325–346.
20. Haneda M, Kojima E, Nishikimi A, Hasegawa T, Nakashima I, Isobe KI. Protein phosphatase 1, but not protein phosphatase 2A, dephosphorylates DNA-damaging stress-induced phospho-serine 15 of p53. FEBS Lett 2004;567:171–174.
21. Li L, Ljungman M, Dixon JE. The human Cdc14 phosphatases interact with and dephosphorylate the tumor suppressor protein p53. J Biol Chem 2000;275:2410–2414.
22. Chen Z, Yi W, Morita Y, Wang H, Cong Y, Liu JP, et al. Wip1 deficiency impairs haematopoietic stem cell function via p53 and mTORC1 pathways. Nat Commun 2015;6:6808.
23. Youlyouz-Marfak I, Gachard N, Le Clorennec C, Najjar I, Baran-Marszak F, Reminieras L, et al. Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ 2008;15:376–385.
24. Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, et al. A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature 2015;519:57–62.
25. Geiger-Maor A, Guedj A, Even-Ram S, Smith Y, Galun E, Rachmilewitz J. Macrophages regulate the systemic response to DNA damage by a cell nonautonomous mechanism. Cancer Res 2015;75:2663–2673.
26. Aydinlik H, Nguyen TD, Moennikes O, Buchmann A, Schwarz M. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of beta-catenin-mutated mouse liver tumors. Oncogene 2001;20:7812–7816.
27. Dong B, Lee JS, Park YY, Yang F, Xu G, Huang W, et al. Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun 2015;6:5944.
28. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011;8:292–301.
29. Fischer M, Goldschmitt J, Peschel C, Brakenhoff JP, Kallen KJ, Wollmer A, et al. I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol 1997;15:142–145.
30. Cairo S, Armengol C, De Reyniès A, Wei Y, Thomas E, Renard CA, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008;14:471–484.
31. Wang H, Park O, Lafdil F, Shen K, Horiguchi N, Yin S, et al. Interplay of hepatic and myeloid signal transducer and activator of transcription 3 in facilitating liver regeneration via tempering innate immunity. Hepatology 2010;51:1354–1362.
32. Kraakman MJ, Kammoun HL, Allen TL, Deswaerte V, Henstridge DC, Estevez E, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab 2015;21:403–416.
33. He JQ, Katschke KJ, Jr., Gribling P, Suto E, Lee WP, Diehl L, et al. CRIg mediates early Kupffer cell responses to adenovirus. J Leukoc Biol 2013;93:301–306.
34. Lanaya H, Natarajan A, Komposch K, Li L, Amberg N, Chen L, et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat Cell Biol 2014;16:972–81, 1-7.
35. Greenhalgh SN, Conroy KP, Henderson NC. Cre-ativity in the liver: transgenic approaches to targeting hepatic nonparenchymal cells. Hepatology 2015;61:2091–2099.
36. Abram CL, Roberge GL, Hu Y, Lowell CA. Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice. J Immunol Methods 2014;408:89–100.
37. Vannella KM, Barron L, Borthwick LA, Kindrachuk KN, Narasimhan PB, Hart KM, et al. Incomplete deletion of IL-4Rα by LysM(Cre) reveals distinct subsets of M2 macrophages controlling inflammation and fibrosis in chronic schistosomiasis. PLoS Pathog 2014;10:e1004372.
38. Rosenbluh J, Nijhawan D, Cox AG, Li X, Neal JT, Schafer EJ, et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012;151:1457–1473.
39. Hoge J, Yan I, Jänner N, Schumacher V, Chalaris A, Steinmetz OM, et al. IL-6 controls the innate immune response against Listeria monocytogenes via classical IL-6 signaling. J Immunol 2013;190:703–711.
40. Hong J, Wang H, Shen G, Lin D, Lin Y, Ye N, et al. Recombinant soluble gp130 protein reduces DEN-induced primary hepatocellular carcinoma in mice. Sci Rep 2016;6:24397.
41. Calabrese LH, Rose-John S. IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014;10:720–727.